Recommendations for treating 2 clinical cases of metastatic breast cancer with antibody-drug conjugates based on supporting data and their adoption into clinical practice.
Funding from Daiichi Sanyko. Content Developed Independently by OncLive.
EP. 1: Antibody-Drug Conjugate Therapy in Metastatic Breast Cancer
Allison Butts, PharmD, BCOP, describes what antibody-drug conjugates are and explains the role in metastatic breast cancer treatment.
EP. 2: ADC Treatment Options and Clinical Data in Breast Cancer
An overview of antibody-drug conjugate therapies available for patients with metastatic breast cancer and triple-negative breast cancer based on outcomes demonstrated in clinical trials.
EP. 3: Adjuvant T-DM1 Therapy for HER2+ Breast Cancer
Impressions regarding the management of a 62-year-old woman with HER2-postive breast cancer who received adjuvant T-DM1 treatment following neoadjuvant TCHP and has signs of residual disease.
EP. 4: Managing Patients With Breast Cancer on T-DM1 Therapy
The types of conversations that breast oncologists should have with their patients with breast cancer before initiating T-DM1, and recommendations for managing treatment-related adverse events.
EP. 5: T-DXd for HER2+ Metastatic Breast Cancer
Recommendations for starting a patient with HER2+ metastatic breast cancer on T-DXd after prior T-DM1 therapy.
EP. 6: Managing Patients With MBC on T-DXd Therapy
Strategies used to help monitor and manage T-DXd treatment-related adverse events.
EP. 7: Sacituzumab Govitecan for TNBC
Komal Jhaveri, MD, FACP, provides rationale for treating a patient with triple-negative breast cancer with sacituzumab govitecan.
EP. 8: Sacituzumab Govitecan Safety Profile in TNBC
Strategies that can be used to mitigate and manage adverse events associated with sacituzumab govitecan therapy for triple-negative breast cancer.
EP. 9: ADC Therapies in Development in Breast Cancer
An overview of novel antibody-drug conjugate therapies currently under investigation as presented at SABCS 2021.
EP. 10: Breast Cancer Treatment: Sequencing With Antibody-Drug Conjugates
Clinical pearls regarding ways to integrate antibody-drug conjugates into treatment algorithms when managing patients with breast cancer.
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL
Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma
Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL
2 Clarke Drive Cranbury, NJ 08512